SVRA stock touches 52-week low at $2.6 amid market challenges

Published 29/01/2025, 19:10
SVRA stock touches 52-week low at $2.6 amid market challenges

In a turbulent market environment, Savara Inc. (NASDAQ:SVRA) stock has reached a 52-week low, dipping to $2.6. According to InvestingPro data, the company maintains strong liquidity with a current ratio of 17.7 and holds more cash than debt on its balance sheet. This price level reflects a significant downturn for the company, which has seen its shares struggle under the weight of various market pressures. Over the past year, the stock has experienced a substantial decline of 45.49%. Despite current challenges, analyst price targets range from $5 to $16, suggesting potential upside opportunities. This downturn highlights the challenges faced by the company in a competitive and ever-changing pharmaceutical landscape, as investors show concern over the company’s performance and future prospects. For deeper insights and additional analysis, including 7 more key ProTips and a comprehensive research report, visit InvestingPro.

In other recent news, Savara Inc. reported earnings per share at ($0.12), slightly missing the ($0.10) forecast by Oppenheimer and consensus estimates. Despite the shortfall, Piper Sandler, H.C. Wainwright, and Oppenheimer maintained their positive ratings on Savara. The company also announced a $100 million stock offering of 26,246,720 shares managed by firms such as Jefferies, Piper Sandler, and Guggenheim Securities. Evercore ISI downgraded the stock from Outperform to In Line and reduced the price target to $5.00. H.C. Wainwright also adjusted Savara’s price target, lowering it from $10.00 to $6.00 due to concerns over the company’s ability to meet patient identification goals for Molbreevi. Savara has set bonus targets for its executive officers for 2025, with actual bonuses contingent upon the achievement of specific performance goals. The company is also on track for potential approval by the end of 2025 for MOLBREEVI™s in autoimmune pulmonary alveolar proteinosis (aPAP), assuming the treatment receives priority review. These are some of the recent developments concerning Savara Inc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.